There is a version of nutritional communication so basic it should be unremarkable: food is substrate. Your body is made of cells; cells require specific inputs to function. Providing those inputs is maintenance of a biological system. Not providing them has consequences. Providing the wrong things has consequences. The system does not negotiate with your feelings about this, your culture’s feelings about this, or the billion-dollar industry that has spent decades making sure you never think about it in these terms.

And yet here we are.

A Constructed Appetite

The life-centric relationship with food is not a biological given. It is a social construction that is heavily amplified, commercially incentivized, and so thoroughly normalized that questioning it reads as aberrant.

There is a real biological signal underneath it. Eating when hungry produces satisfaction, flavor and texture produce sensory response. But the idea that food is one of life’s primary pleasures, that a meal should be an experience, that eating decadently is central to human joy — this is a cultural overlay, and a monetized one. We built elaborate ritual around it, told each other the story repeatedly, and the food industry engineered products specifically to exploit and amplify the reward signal far beyond anything the original biology intended.

The brain’s reward architecture was calibrated for scarcity. It runs a program that made sense for most of human evolutionary history: prioritize caloric density, seek sugar and fat, eat beyond immediate need when food is available because tomorrow is uncertain. That program is now executing in an environment of engineered hyperpalatable abundance specifically designed to exploit it.

The result is a population following an incompatible signal and calling it pleasure.

Overconsumption of substances that cells cannot cleanly process is not enjoying food. It is addiction presenting as enjoyment. The dopamine response is real; the nourishment is not. These are separable facts that the culture and the profit motive leveled into one.

On the opposite end: restriction as identity, as control, as the primary arena for self-discipline and moral worth. Also not a healthy relationship with food. Also a cultural construction, differently monetized, differently mythologized, equally damaging to the biological substrate.

Both ends of this spectrum share a common error: they locate the meaning of food somewhere other than in what it actually does to the cells.

The Performance Window

Nowhere is the gap between appearance and biology more precisely engineered than in professional performance.

Elite athletes have teams organized around a single KPI: sustained physical output within a performance window. The sports medicine physician, the dietitian, the strength coach — all optimizing for the same thing. Keeping the athlete functional and competitive is instrumentally valuable because a broken athlete cannot perform. The financial incentive and the health incentive are aligned within that window. Periodization builds in recovery. Baseline testing tracks longitudinal trends. When something deviates, the system corrects it before it costs performance.

But the window is not a lifetime. Depending on the sport, elite careers span somewhere between 5 and 20 years. The optimization is for output during that period, not for what the body looks like at 60. The accumulated load of elite sport carries its own tab: joint degradation, cardiac remodeling from decades of high-intensity training, elevated atrial fibrillation rates in endurance athletes, structural compromises from repeated injury and repair. Former NFL players carry significantly reduced life expectancy. The transition out of an elite sport means the athlete’s training load drops suddenly and the body is left to absorb two decades of accumulated stress without the infrastructure that managed it. It is not surprising that this shift is often poorly handled and poorly studied.

Athletes are better optimized than actors for sustained output within their careers. The teams are more competent, the incentive structure more coherent, the near-term health management more rigorous. But both models involve using the body hard in service of external demands. Both carry a tab. The difference is timing and visibility, not the existence of a cost.

Actors have teams organized around a different KPI: looking a specific way by a specific date. The trainer, the nutritionist, the wellness consultant, are all optimizing for the camera. The studio has no stake in what happens to the actor’s thyroid or bone density in fifteen years. The financial incentive and the health incentive are decoupled from the start.

The result is precise body engineering in service of appearance: bulk and cut cycles compressed into impossible timelines, acute dehydration for camera-ready vascularity, pharmaceutical support that produces the look without the underlying physiology. What appears on screen is not a state the body inhabits. It is a state the body was forced into briefly, at cost, and will not sustain.

The feedback loop is the cruelest part. Lean, muscular, high energy from stimulants and peptides, skin luminous from growth hormone — the aesthetic result actively contradicts the physiological reality. The instrument being used to assess health is calibrated to appearance; appearance is lying.

The body compensates remarkably well. Thyroid dysregulation, bone density loss, hormonal suppression, cardiac hypertrophy — these accumulate for years before anything surfaces as a symptom you would notice. By the time the signal arrives, the damage has been running for a decade.

The Male Performance Asset

The male body in high-performance contexts is treated as an asset to be optimized, and the optimization is almost entirely invisible as a cultural phenomenon because it aligns so precisely with existing narratives about male discipline, commitment, and physical capability.

The male performance ideal has escalated dramatically over the past three decades. The physiques considered normal for leading men in the 1980s would not be cast in the same roles today. What the culture now reads as a natural male body — the superhero physique, the action franchise baseline — is largely a pharmaceutical artifact, normalized through repetition until it became the reference point against which real bodies are measured and found insufficient. Men growing up with this as the standard are calibrating against something that does not exist without chemical assistance. Many are pursuing it accordingly, and not only in Hollywood. TRT and anabolic use has expanded steadily into recreational fitness culture, well beyond the performance contexts where it originated.

The HPTA suppression problem is almost entirely absent from public conversation. Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis. The testes downregulate and natural production drops. With prolonged use this can become permanent. Men who begin testosterone supplementation in their thirties for body composition reasons may require exogenous hormone for life, not because their natural production was clinically insufficient to begin with, but because the intervention made it so.

Cardiac consequences accumulate on a similar timeline. Heavy resistance training, supraphysiologic androgen exposure, and stimulant use for energy and fat burning contribute collectively to pathological cardiac remodeling: left ventricular hypertrophy, reduced diastolic function, erythrocytosis that increases clot risk. These are documented in long-term anabolic users, and the signals appear at lower doses and shorter durations than the culture assumes are dangerous. The man who has been running a “moderate” protocol for ten years has a cardiac history the culture has no framework to recognize as such.

The eating disorder gap compounds all of this. Disordered eating in men is dramatically underdiagnosed because the clinical template was built around female presentation. The male version frequently presents as orthorexia or muscle dysmorphia: obsessive dietary precision, excessive protein tracking, inability to deviate from the training schedule, body image distorted toward perceiving insufficient size rather than insufficient thinness. These are not culturally legible as disorders. They read as dedication. The man weighing his food and training twice daily is admired. The substrate cost of what he is doing is invisible because the behavior looks exactly like what the culture rewards.

And men do not discuss any of this with each other. The pharmaceutical use is widespread in certain contexts and almost entirely unacknowledged publicly. The physical and psychological costs are carried privately. There is no male equivalent of the cultural conversation, however inadequate, that exists around women and body image. That silence doesn’t protect anyone. It just makes the damage harder to see until it surfaces as something that can no longer be attributed to anything else.

The Female Performance Asset

Women face a version of this that is more physiologically aggressive and more culturally obscured.

The female performance ideal has long demanded thinness, a standard with roots stretching back decades through heroin chic, through Twiggy, through successive iterations of the same basic requirement that a woman’s body occupy as little space as possible. What has shifted recently is the addition of visible muscle to that demand: more visibly athletic, the “strong” aesthetic that shows defined arms, visible abdominal muscle, the appearance of physical capability. This looks like progress. It is partially progress. But the core demand has not changed as much as the surface suggests.

The new ideal still requires low body fat alongside the visible muscle. That combination — lean enough to show definition, muscular enough to read as strong — is actually a narrower and more pharmacologically demanding target than simple thinness was. The HPG axis and bone density problems don’t disappear when the aesthetic shifts from thin to toned. They arrive in different packaging. And the “toned” look, produced on a filming timeline, is frequently a pharmaceutical story: the anavar, the peptides, the aggressive training protocol that gets a woman visibly muscular at low body fat in the months available before shooting. The result looks like health and capability. The process that produced it often isn’t sustainable, and the body composition it requires carries the same systemic costs it always did.

The ideal is also role and genre dependent. Action franchises and superhero films have normalized visible female muscularity in ways that were genuinely uncommon twenty years ago. The romantic lead, the prestige drama actress, and the woman over forty in a leading role still track closer to the earlier thin ideal. The shift is real in specific contexts and largely cosmetic in others.

What hasn’t shifted: the female performance ideal remains organized around appearance rather than function, still demands low body fat as a baseline condition, and still extracts the same physiological price regardless of which aesthetic variation is currently in fashion. That requires sustaining low body fat without the anabolic support that muscle mass provides, or with pharmaceutical support that produces the look without the underlying physiology. Either way it is a harder state to maintain and more costly to the body long-term than the culture’s celebration of the strong female aesthetic acknowledges.

Below roughly 16-18% body fat, the HPG axis downregulates. LH and FSH drop. Estrogen drops. Cycles become irregular or stop. This is hypothalamic amenorrhea — the body reading sustained energy deficit as famine and suspending reproduction. Bone density loss follows estrogen loss, and it does not fully reverse. The woman sustaining this through her thirties is setting up fragility fractures in her sixties and seventies.

Cardiovascular protection erodes with estrogen; cognitive function degrades; mood destabilizes; sleep architecture deteriorates. These are reliably attributed to personality, stress, aging — anything except the underlying hormonal suppression that is their actual cause.

The pharmaceutical landscape available to women in high-performance contexts is its own problem, and GLP-1 agonists are its clearest current example.

These drugs are genuinely valuable in specific populations: people with type 2 diabetes or significant metabolic dysfunction, where the cardiovascular and metabolic benefits are well-documented and the risk-benefit calculation is straightforward. That is the population the clinical trials studied. It is not the population currently using them at scale in Hollywood and beyond.

In lean users taking them for aesthetic body composition purposes, the picture is substantially different and largely unexamined. The metabolic markers improve on paper. The body composition outcome may be net negative. Across the GLP-1 drug class, approximately 25% of weight lost is lean mass rather than fat. With the high-dose semaglutide and tirzepatide formulations that dominate aesthetic use — the most potent, the most widely prescribed, the ones producing the results Hollywood is actually after — that figure rises to approximately 40%.

The industry response to this data is instructive. The standard reassurance is that lean mass as a proportion of total body mass remains unchanged, meaning the ratio of muscle to fat stays roughly constant even as absolute muscle tissue is lost. This is a denominator choice, not a finding. It answers the question of whether the drug selectively catabolizes muscle relative to fat, which is a question about pharmacological mechanism. It does not answer the question of whether the person ends up with less functional muscle tissue than they started with, which is the question that matters. Absolute lean mass is what drives resting metabolic rate, protects joints, maintains insulin sensitivity, and determines functional capacity at seventy. None of those outcomes care what percentage of body mass the muscle represents. Selecting the denominator that produces the reassuring answer and presenting it as reassuring is not an error in statistical reasoning. It is a precise application of it.

This is not a cosmetic problem. Lean mass loss degrades resting metabolic rate, insulin sensitivity, functional capacity, and the body’s resilience to aging. Each cycle of use followed by discontinuation preferentially restores fat while lean mass lags. The person who cycles on and off may return to the same number on the scale while their actual body composition shifts unfavorably with each round.

Bone density decreases with use, partly from lean mass loss and partly from reduced mechanical loading. The fracture risk data is not yet mature but the signal is present and being watched.

The gastrointestinal effects are widely known because they are immediate. Less widely known: cases of severe gastroparesis persisting after discontinuation have been reported. The mechanism of action — slowed gastric emptying — that produces satiety can become pathological in some users, and it does not always resolve.

The psychiatric signal is underreported relative to its significance. Post-marketing surveillance flagged suicidal ideation and depression, and the FDA updated the label. The mechanism is not fully established, but GLP-1 receptors are present in the brain and the drugs affect reward signaling broadly, not just in appetite. These compounds are being used at scale in people whose dopamine and reward architecture is not metabolically dysregulated, and we have essentially no long-term data on what chronic reward pathway modulation does to that population. The psychiatric signal may be an early readout of something larger that the trials, conducted in a different population for a different duration, were not designed to detect.

Rodent studies showed thyroid C-cell tumors with GLP-1 agonist exposure. Human translation remains contested. The current literature calls it a possible signal rather than established risk, but it is on the label as a contraindication for anyone with personal or family history of medullary thyroid carcinoma. This is essentially unknown outside clinical circles despite widespread use.

The deeper problem is structural. The entire evidence base for these drugs comes from populations with metabolic dysfunction. The risk-benefit calculation for a lean person using them for aesthetic purposes is a completely different equation, and it has not been assessed. The drugs are being deployed at enormous scale in a context that the science does not cover, the aesthetic feedback is positive, the cultural narrative is celebratory, and the physiological consequences are accumulating in exactly the way the central argument of this piece predicts they would.

The appearance of the thing is not the thing itself.

Thyroid manipulation with exogenous T3 follows the same pattern: accelerates fat burning, and with repeated use can permanently alter the feedback loop. The gland downregulates, and natural production doesn’t always recover. The person who manages their way to a leaner body through repeated thyroid manipulation may spend the rest of their life dependent on exogenous hormone because the system they overrode never fully came back online.

And the research framing around women and food is almost entirely constructed against a baseline of normal American eating, which is itself pathological by any rigorous nutritional biology standard. The clinical literature measures deviation from a broken baseline and calls movement toward it health. The woman who eats precisely for cellular function appears in this framework as restrictive, disordered, a clinical concern. The woman consuming 80 grams of added sugar daily appears as normal.

The instrument is miscalibrated. We keep using it anyway.

Biology’s Real Baseline

The coherent relationship with food is not pleasureless. It is not anxious. It is not moralized.

It is this: food is substrate. Cells require specific inputs. The goal is to provide those inputs reliably, at sufficient quantity, from sources the body can actually process. Everything else is noise.

There is real sensory pleasure in eating real food. Flavor exists. Texture exists. Satisfaction from eating when hungry is a genuine biological signal worth respecting. None of this needs to be suppressed or denied.

What does not need to be true: that food is a primary source of joy. That meals are experiences. That eating well is one of life’s central pleasures. These are stories we tell each other, amplified by industry, and they have done significant damage by centering the pleasure budget on a system that was never designed to carry it.

Pleasure is not exclusive to food. Physical capability produces it, mastery produces it, connection produces it, creative work produces it. A life in which food occupies its actual biological proportion: maintenance, with some sensory enjoyment, leaves the rest of the pleasure budget available for things that are better at filling it and less physiologically costly when overused.

A brain accustomed to sugar spikes and excess intake. will push back on this. It will generate wanting that feels like need, reward that feels like nourishment, craving that feels like preference. This is the program running. It is not a guide to what the cells actually require.

Managing against a broken signal is not restriction. It is not disorder. It is not moralizing.

It is simply respecting the biological substrate you are living in.

The substrate doesn’t care how you feel about it. It will tell you the truth eventually, whether you asked or not.

Sources

Food as substrate / evolutionary reward architecture and modern mismatch

Guyenet, S. (2017). The Hungry Brain. Flatiron Books.

Kessler, D. (2009). The End of Overeating. Rodale Press.

Moss, M. (2013). Salt Sugar Fat. Random House.

Nesse, R. & Williams, G. (1994). Why We Get Sick. Vintage Books.

Monteiro, C.A. et al. (2019). Ultra-processed foods: what they are and how to identify them. Public Health Nutrition, 22(5), 936-941.

Poti, J.M. et al. (2015). Is the degree of food processing and convenience linked with the nutritional quality of foods purchased by US households? American Journal of Clinical Nutrition, 101(6), 1251-1262.

Schultz, W. (2015). Neuronal reward and decision signals: from theories to data. Physiological Reviews, 95(3), 853-951.

Kenny, P.J. (2011). Reward mechanisms in obesity: new insights and future directions. Neuron, 69(4), 664-679.

Lustig, R. (2021). Metabolical. HarperWave.

Athletic career length and post-career physical and mental health

Gouttebarge, V., Castaldelli-Maia, J.M., Gorczynski, P., et al. (2019). Occurrence of mental health symptoms and disorders in current and former elite athletes: a systematic review and meta-analysis. British Journal of Sports Medicine, 53(11), 700-706. https://pubmed.ncbi.nlm.nih.gov/31097451/

Gouttebarge, V., Inklaar, H., Backx, F., & Kerkhoffs, G. (2015). Prevalence of osteoarthritis in former elite athletes: a systematic overview of the recent literature. Rheumatology International, 35(3), 405-418. https://pubmed.ncbi.nlm.nih.gov/25037899/

Gouttebarge, V., Aoki, H., & Kerkhoffs, G.M.M.J. (2018). Lower extremity osteoarthritis is associated with lower health-related quality of life among retired professional footballers. The Physician and Sportsmedicine, 46(4), 471-476. https://pubmed.ncbi.nlm.nih.gov/29527975/

Carmody, S., Anemaat, K., Massey, A., Kerkhoffs, G., & Gouttebarge, V. (2022). Health conditions among retired professional footballers: a scoping review. BMJ Open Sport & Exercise Medicine. https://pubmed.ncbi.nlm.nih.gov/35528132/

Le Roux, J., Anema, F., Janse van Rensburg, D.C., Kerkhoffs, G., & Gouttebarge, V. (2023). Health conditions among retired elite rugby players: a scoping review. BMJ Open Sport & Exercise Medicine, 9(3), e001573. https://pubmed.ncbi.nlm.nih.gov/37547127/

Gouttebarge, V. & Kerkhoffs, G.M.M.J. (2021). Sports career-related concussion and mental health symptoms in former elite athletes. Neurochirurgie, 67(3), 280-282. https://pubmed.ncbi.nlm.nih.gov/32017942/

Abdulla, J. & Nielsen, J.R. (2009). Is the risk of atrial fibrillation higher in athletes than in the general population? European Heart Journal, 30(13). doi:10.1093/eurheartj/ehp111.

Nguyen, V.T. et al. (2021). Cardiovascular mortality among NFL players. American Journal of Cardiology.

Male body image, muscle dysmorphia, anabolic use, and underdiagnosis

Pope, H.G., Phillips, K.A., & Olivardia, R. (2000). The Adonis Complex. Free Press.

Leit, R.A., Gray, J.J., & Pope, H.G. (2002). The media’s representation of the ideal male body: a cause for muscle dysmorphia? International Journal of Eating Disorders, 31(3), 334-338.

Pope, H.G. et al. Published extensively on anabolic steroid use and HPTA suppression. Search: Pope HG anabolic steroids HPTA. Biological Psychiatry and Drug and Alcohol Dependence.

HPG axis suppression, hypothalamic amenorrhea, and bone density in women

Loucks, A.B. (2003). Energy availability, not body fatness, regulates reproductive function in women. Exercise and Sport Sciences Reviews, 31(3), 144-148.

Loucks, A.B. & Thuma, J.R. (2003). Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. Journal of Clinical Endocrinology and Metabolism, 88(1), 297-311.

Ackerman, K.E. et al. (2019). Relative Energy Deficiency in Sport (RED-S). British Journal of Sports Medicine.

American College of Sports Medicine Position Stand on the Female Athlete Triad. Medicine & Science in Sports & Exercise, 2007.

GLP-1 agonists: lean mass loss and body composition

Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C.S. (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism: Clinical and Experimental, 164, 156113. https://pubmed.ncbi.nlm.nih.gov/39719170/

Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384, 989-1002.

GLP-1 agonists

Rubino, D.M. et al. (2022). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. Diabetes, Obesity and Metabolism.

Sodhi, M. et al. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 330(18), 1795-1797.

FDA prescribing information for semaglutide (Ozempic/Wegovy). Current label. https://www.accessdata.fda.gov/scripts/cder/daf/

FDA prescribing information for semaglutide. Boxed warning, medullary thyroid carcinoma. https://www.accessdata.fda.gov/scripts/cder/daf/

Krupa, A. et al. (2025). Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry. European Neuropsychopharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC12244148/

Bormann, N.L. et al. (2025). The potential role of GLP-1 receptor agonists in substance use disorders: a systematic review. Frontiers in Pharmacology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808432/

Psychiatric effects of GLP-1 receptor agonists: a systematic review of emerging evidence. (2026). Diabetes, Obesity and Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12673456/

Thyroid manipulation and HPT axis feedback loop disruption

Sawin, C.T. et al. (1975). Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. New England Journal of Medicine, 293(14). https://pubmed.ncbi.nlm.nih.gov/808728/

Vagenakis, A.G. et al. (1975). Patterns of recovery of the hypothalamic-pituitary-thyroid axis in patients taken off chronic thyroid therapy. Journal of Clinical Endocrinology and Metabolism, 41(1), 70-80. https://pubmed.ncbi.nlm.nih.gov/807596/

Leung, A.M. et al. (2021). Clinical outcomes after discontinuation of thyroid hormone replacement: a systematic review and meta-analysis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8110016/

Miscalibrated research baseline

Monteiro, C.A. et al. (2019). Ultra-processed foods: what they are and how to identify them. Public Health Nutrition, 22(5), 936-941.

Poti, J.M. et al. (2015). Is the degree of food processing and convenience linked with the nutritional quality of foods purchased by US households? American Journal of Clinical Nutrition, 101(6), 1251-1262.

Lustig, R. (2021). Metabolical. HarperWave.